Qiagen NVXTER:QIA +1.57%69 OCF Yield % is 7.62 as of Jul. 03, 2026, which is 56% above its 10-year median of 4.90. GuruFocus rates XTER:QIA with a GF Score™ of 69/100 and a GF Value™ of €46.34 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 214 Medical Diagnostics & Research companies, Qiagen NV ranks better than 75.23% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Qiagen NV's OCF Yield % or its related term are showing as below:
XTER:QIA'
s OCF Yield % Range Over the Past 10 Years
Min: 2.31 Med: 4.9 Max: 8.93
Current: 7.62
During the past 13 years, the highest OCF Yield % of Qiagen NV was 8.93%. The lowest was 2.31%. And the median was 4.90%.
XTER:QIA's OCF Yield % is ranked better than 75.23% of 214
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.02
vs XTER:QIA: 7.62
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Qiagen NV OCF Yield % Related Terms
Qiagen NV OCF Yield % Historical Data
* Premium members only.
The historical data trend for Qiagen NV's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTER:QIA vs TWST, CRL, BLLN: OCF Yield % Comparison
For the Diagnostics & Research subindustry, Qiagen NV's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Qiagen NV OCF Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Qiagen NV's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Qiagen NV's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Qiagen NV (XTER:QIA) has a OCF Yield % of 7.62 as of Jul. 03, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Qiagen NV and its competitors. This is 56% above median its historical median of 4.90. Over the past decade, Qiagen NV's OCF Yield % has ranged from 2.31 to 8.93. According to the industry distribution chart, Qiagen NV ranks #53 out of 214 companies in the Medical Diagnostics & Research industry, placing it in the top 24.8%.
Is Qiagen NV's OCF Yield % too high?
Qiagen NV's current OCF Yield % of 7.62 is 56% above median its 10-year median of 4.90. Over the past 10 years, this metric has ranged from a low of 2.31 to a high of 8.93. The Medical Diagnostics & Research industry median OCF Yield % is 1.02. Qiagen NV's value of 7.62 is 647.1% above this industry median. Based on the distribution chart, Qiagen NV ranks #53 out of 214 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Qiagen NV has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Qiagen NV's OCF Yield % compare to TWST and CRL?
According to the Medical Diagnostics & Research industry distribution chart, Qiagen NV ranks #53 out of 214 companies for OCF Yield %. This places Qiagen NV in the top 25% of its industry — outperforming the majority of peers. The industry median OCF Yield % is 1.02. Qiagen NV's value of 7.62 is 647.1% above this benchmark. Historically, Qiagen NV's own OCF Yield % has ranged from 2.31 to 8.93 over the past decade. While the company's 10-year median is 4.90 vs. the industry median of 1.02, Qiagen NV has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Medical Diagnostics & Research company?
The median OCF Yield % among Medical Diagnostics & Research companies is 1.02, based on 214 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Qiagen NV's current OCF Yield % of 7.62 is 647.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Qiagen NV and its competitors. For the Medical Diagnostics & Research industry, the median OCF Yield % is 1.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Qiagen NV's current OCF Yield % is 7.62, which is 56% above median its own 10-year median of 4.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qiagen NV stock overvalued right now?
Based on GuruFocus' analysis, Qiagen NV (XTER:QIA) is currently considered Modestly Undervalued. The stock's GF Value™ is €46.34, compared to a current price of €34.98 — trading 24.5% below its estimated fair value. The current OCF Yield % is 7.62, which is 56% above median its 10-year median of 4.90 and 647.1% above the Medical Diagnostics & Research industry median of 1.02. Qiagen NV's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Qiagen NV (XTER:QIA), the current OCF Yield % is 7.62 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Qiagen NV (XTER:QIA) Overvalued in 2026?
Based on GuruFocus' analysis, Qiagen NV stock appears to be undervalued.
The current stock price of €34.98 is trading 24.5% below its estimated GF Value™ of €46.34.
GuruFocus considers Qiagen NV to be Modestly Undervalued.
Key valuation signals for XTER:QIA:
OCF Yield %: 7.62 (56% above median its 10-year median of 4.90)
GF Value™: €46.34 vs. price of €34.98 (24.5% below fair value)
Industry Position: 647.1% above the Medical Diagnostics & Research median (#53 of 214)
No single metric tells the full story. See the XTER:QIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).
69GF Score
Get the complete analysis for XTER:QIA
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTER:QIA has been successfully added to your 
